CheckMate649 5-Year Follow-Up, Study Design, and Efficacy Results
Panelists discuss how the CheckMate649 study was a randomized trial that compared nivolumab plus FOLFOX (leucovorin, fluorouracil, oxaliplatin) chemotherapy with chemotherapy alone for treating advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. The study results found that nivolumab plus chemotherapy improved overall survival and progression-free survival compared with chemotherapy alone.
EP: 1.Treatment Landscape and Unmet Needs in Advanced Gastric Cancers
EP: 2.CheckMate649 5-Year Follow-Up, Study Design, and Efficacy Results
EP: 3.Evaluating Long-Term Outcomes and Personalized Treatment Strategies in Advanced Gastrointestinal Cancers
EP: 4.Assessing the Long-Term Safety and Efficacy of Nivolumab Plus Chemotherapy for Broader Clinical Adoption in Advanced GI Cancers
EP: 5.Balancing Treatment Intensity, Quality of Life, and Biomarker-Driven Approaches in Advanced GI Cancers
EP: 6.Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers
EP: 7.Key Takeaways and Future in Advanced Gastric Cancer Treatment
EP: 8.Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
